Guardant Health and Nuvalent agreed to collaborate on oncology companion diagnostics across multiple clinical studies. Guardant will supply tissue and liquid biopsy tools to support Nuvalent’s global oncology programs and to evaluate whether Guardant assays can become companion diagnostics to support potential regulatory submissions. The companies also plan to align on commercialization if Nuvalent’s candidates receive approvals. While financial terms were not disclosed, the collaboration reflects continued integration of liquid biopsy platforms into regulatory strategies for precision oncology. For development teams, the announcement reinforces how diagnostic partners are positioning early to reduce timeline risk when biomarker evidence becomes required for label expansion.